Quick Answer
GALECTIN THERAPEUTICS INC reported Net Income of -$30.84 million for fiscal year 2025.
GALECTIN THERAPEUTICS INC Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$30.84M | +34.5% |
| 2024 | -$47.05M | -14.6% |
| 2023 | -$41.07M | -5.9% |
| 2022 | -$38.78M | -27.0% |
| 2021 | -$30.53M | -30.1% |
| 2020 | -$23.46M | -76.5% |
| 2019 | -$13.29M | +4.4% |
| 2018 | -$13.90M | +14.4% |
| 2017 | -$16.23M | +24.3% |
| 2016 | -$21.44M | -7.0% |
| 2015 | -$20.03M | -26.8% |
| 2014 | -$15.79M | -30.6% |
| 2013 | -$12.09M | -24.9% |
| 2012 | -$9.68M | +11.4% |
| 2011 | -$10.91M | -93.9% |
| 2010 | -$5.63M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.18M | +27.1% | -8.8% |
| June 30, 2025 | -$7.52M | +39.2% | +21.9% |
| March 31, 2025 | -$9.63M | +16.2% | +14.2% |
| September 30, 2024 | -$11.22M | -7.6% | +9.3% |
| June 30, 2024 | -$12.37M | -35.7% | -7.7% |
| March 31, 2024 | -$11.49M | +0.3% | -10.2% |
| September 30, 2023 | -$10.43M | -21.3% | -14.4% |
| June 30, 2023 | -$9.11M | +5.2% | +20.9% |
- GALECTIN THERAPEUTICS INC showed an increase of +34.5% in Net Income compared to the prior fiscal year.
- Over the 2010–2025 period, GALECTIN THERAPEUTICS INC’s net income has declined by 447.8% (from -$5.63 million to -$30.84 million).
- The most recent figure is from GALECTIN THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: